NASDAQ · ELAN
Healthcare · Drug Manufacturers - Specialty & Generic
$22.42
Down-$0.32 (-1.41%)
Updated Sep 20, 2026, 2:26 PM
SID Score
4.3/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
ELAN closed at $22.42 after 19 trading sessions, down 8.19% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $22.77 | $22.88 | $22.275 | $22.42 | 7.95M |
| Sep 17, 2026 | $23.34 | $23.63 | $22.725 | $22.74 | 4.61M |
| Sep 16, 2026 | $23.08 | $23.40 | $22.685 | $22.86 | 7.03M |
| Sep 15, 2026 | $23.16 | $23.47 | $22.65 | $23.00 | 8.25M |
| Sep 14, 2026 | $23.50 | $23.52 | $23.02 | $23.15 | 3.88M |
| Sep 11, 2026 | $23.20 | $23.32 | $22.65 | $23.17 | 4.74M |
| Sep 10, 2026 | $23.37 | $23.61 | $22.86 | $22.86 | 5.63M |
| Sep 9, 2026 | $23.91 | $23.96 | $23.495 | $23.55 | 3.88M |
| Sep 8, 2026 | $24.37 | $24.38 | $23.87 | $23.97 | 3.91M |
| Sep 4, 2026 | $24.20 | $24.71 | $24.00 | $24.50 | 3.72M |
| Sep 3, 2026 | $24.94 | $25.065 | $23.74 | $24.42 | 5.92M |
| Sep 2, 2026 | $23.97 | $24.92 | $23.87 | $24.68 | 6.74M |
| Sep 1, 2026 | $24.04 | $24.395 | $23.90 | $23.91 | 3.95M |
| Aug 31, 2026 | $23.97 | $24.015 | $23.41 | $23.92 | 5.36M |
| Aug 28, 2026 | $24.45 | $24.755 | $23.99 | $24.11 | 4.17M |
| Aug 27, 2026 | $24.91 | $25.04 | $24.42 | $24.49 | 4.09M |
| Aug 26, 2026 | $25.02 | $25.19 | $24.84 | $25.08 | 4.15M |
| Aug 25, 2026 | $24.60 | $25.405 | $24.46 | $25.09 | 5.31M |
| Aug 24, 2026 | $24.11 | $24.54 | $24.03 | $24.42 | 3.95M |
The latest Smart Investors Daily articles mentioning ELAN.
ELAN research
Company profile and research snapshot.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Keybanc | Overweight | — |
| Aug 6, 2026 | UBS | Buy | — |
| Jul 22, 2026 | Morgan Stanley | Equal-Weight | — |
| Jun 18, 2026 | TD Cowen | Buy | — |
| May 7, 2026 | Citigroup | Buy | — |
Generated Sep 20, 2026, 11:19 AM
Elanco Animal Health shares declined 1.41% today, closing down $0.32, as the market digests the company's announcement to participate in the BofA Securities Global Healthcare Conference 2026. While the conference participation itself is routine corporate activity, the modest decline suggests investors may be awaiting more substantive catalysts or guidance from management.
Bottom line: Today's modest 1.41% decline appears disconnected from any negative fundamentals, with the BofA Securities Conference participation representing routine engagement rather than material news. Investors should monitor the actual conference presentation for substantive updates on growth strategy, product pipeline, or financial guidance that could reignite positive momentum in the stock.
Yahoo · Sep 17, 2026
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026. Jeff Simmons, president and CEO, will participate in a fireside chat on Tuesday, September 22 at 2:10 p.m. BST (9:10 a.m. EDT).
Yahoo · Sep 15, 2026
Elanco currently trades at $23.15 per share and has shown little upside over the past six months, posting a small loss of 1.1%. The stock also fell short of the S&P 500’s 14.2% gain during that period.
SeekingAlpha · Sep 15, 2026
Elanco Animal Health Incorporated (ELAN) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 2:35 PM EDTCompany ParticipantsJeffrey...
Yahoo · Sep 15, 2026
* Innovation that protects against these pests is driving stronger base business and overall share gains. Pet Health is on track to expectations of high-single digit to low double-digit growth in the second half of 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ELAN.
